We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+20.07%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$530M
AUM Growth
-$28.3M
Cap. Flow
-$54.8M
Cap. Flow %
-10.35%
Top 10 Hldgs %
67.2%
Holding
99
New
35
Increased
16
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$5.65M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$5.31M
3
VRAY
ViewRay, Inc.
VRAY
+$4.67M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.21M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.69M

Top Sells

Rank Stock Value
1
DBVT
DBV Technologies
DBVT
+$8.15M
2
FOLD
Amicus Therapeutics
FOLD
+$3.52M
3
NVTA
Invitae Corporation
NVTA
+$3.37M
4
FBRX icon
Forte Biosciences
FBRX
+$3.13M
5
PDSB icon
PDS Biotechnology
PDSB
+$3.11M

Sector Composition

Rank Sector Weight
1 Healthcare 51.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNC icon
76
PUT
Centene
CNC
$31.5B
– –
-40,000
Closed -$1.94M
DBVT
77
CALL
DBV Technologies
DBVT
$804M
– –
-900
Closed -$382K
DBVT
78
DBV Technologies
DBVT
$804M
– –
-19,200
Closed -$8.15M
DBVT
79
PUT
DBV Technologies
DBVT
$804M
– –
-20,000
Closed -$8.49M
FBRX icon
80
Forte Biosciences
FBRX
$1.57B
– –
-670
Closed -$3.13M
FOLD
81
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-151,000
Closed -$2.28M
GOGO icon
82
PUT
Gogo Inc
GOGO
$606M
– –
-135,000
Closed -$1.59M
JNJ icon
83
PUT
Johnson & Johnson
JNJ
$613B
– –
-45,000
Closed -$5.85M
SIOX
84
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-2,538
Closed -$140K
LCI
85
PUT
DELISTED
Lannett Company, Inc.
LCI
– –
-31,875
Closed -$2.35M
OTIC
86
CALL
DELISTED
Otonomy, Inc.
OTIC
– –
-17,500
Closed -$57K
CLVS
87
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-80,000
Closed -$6.59M
QTNT
88
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-14,229
Closed -$2.81M
ALXN
89
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-15,000
Closed -$2.1M
IMMU
90
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-667,500
Closed -$9.33M
AIMT
91
DELISTED
Aimmune Therapeutics
AIMT
– –
-58,525
Closed -$1.45M
PTLA
92
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-20,000
Closed -$1.08M
RARX
93
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-71,500
Closed -$1.04M
NITE
94
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
– –
-100,000
Closed -$1.92M
ONSIW
95
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
– –
-96,833
Closed -$12K
ONSIZ
96
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
– –
-96,833
Closed -$5K
CBMXW
97
DELISTED
CombiMatrix Corporation Warrant
CBMXW
– –
-564,200
Closed -$1.41M
CBMX
98
DELISTED
CombiMatrix Corporation
CBMX
– –
-111,912
Closed -$839K
ZGNX
99
PUT
DELISTED
Zogenix, Inc.
ZGNX
– –
-160,000
Closed -$5.61M
1 2 3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2017 Portfolio in Review

As of Q4 2017, Acuta Capital Partners held 99 positions worth $530M, down 5.1% from $558M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Acuta Capital Partners withdrew a net $54.8M in Q4 2017, closing 25 positions and reducing 15 holdings. Its most notable exit was DBV Technologies, an estimated $8.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in AveXis, Inc. Common Stock worth $5.85M.

  • Acuta Capital Partners's largest Q4 2017 buy was AveXis, Inc. Common Stock: 52,900 shares worth $5.85M.
  • Acuta Capital Partners added most to Kadmon Holdings, Inc. in Q4 2017, an estimated $5.65M increase.
  • Acuta Capital Partners's biggest Q4 2017 reduction was Amicus Therapeutics, cutting an estimated $3.52M.
  • Acuta Capital Partners fully exited DBV Technologies in Q4 2017, selling an estimated $8.15M.
  • Acuta Capital Partners's ten largest holdings make up 67% of its $530M portfolio in Q4 2017.
  • Acuta Capital Partners opened 35 new positions and closed 25 in Q4 2017.
  • Acuta Capital Partners's portfolio value fell 5.1% quarter-over-quarter to $530M.

Based on Acuta Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.